Mucosal melanoma

Summary

Mucosal melanoma (MONDO:0000544) is a cancer with 2 cohort genes (2 CIViC-evidence somatic drivers) and 61 clinical trials. Molecularly, KIT Amplification is associated with resistance to Imatinib in Mucosal Melanoma (CIViC Level B); 2 further subtype–drug associations are mapped below. Top therapeutic interventions include toripalimab, sorafenib, and axitinib.

At a glance

• Classification: Cancer
• Cohort genes: 2
• Clinical trials: 61
• Precision-medicine evidence (CIViC): 3 subtype–drug associations

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	mucosal melanoma
Mondo ID	MONDO:0000544
DOID	DOID:0050929
NCIT	C114828
UMLS	C3898222
MedGen	857816
Is cancer (heuristic)	yes

Also known as: mucosal melanoma

Data availability: 10 cell lines.

Disease family

An umbrella term covering 2 Mondo subtypes.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › melanocytic neoplasm › melanoma › non-cutaneous melanoma › mucosal melanoma

Related subtypes (3): vulvar melanoma, primary melanoma of the central nervous system, digestive system melanoma

Subtypes (2): cervix melanoma, vaginal melanoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 26 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Somatic driver evidence (intOGen + CIViC, cohort fanout)

Gene	intOGen role	Cancer types	CIViC
ALK	Act	BRCA,HCC,NBL,NSCLC,PROSTATE,SCLC	CIViC #1
KIT	Act	AML,GIST,MEL,MGCT	CIViC #29

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
ALK	Orphanet:146	Differentiated thyroid carcinoma
ALK	Orphanet:178342	Inflammatory myofibroblastic tumor
ALK	Orphanet:251877	Ganglioneuroblastoma
ALK	Orphanet:251992	Ganglioneuroma
ALK	Orphanet:300895	ALK-positive anaplastic large cell lymphoma
ALK	Orphanet:364043	ALK-positive large B-cell lymphoma
ALK	Orphanet:626	Large/giant congenital melanocytic nevus
ALK	Orphanet:635	Neuroblastoma
KIT	Orphanet:102724	Acute myeloid leukemia with t(8;21)(q22;q22) translocation
KIT	Orphanet:158766	Typical urticaria pigmentosa
KIT	Orphanet:158769	Plaque-form urticaria pigmentosa
KIT	Orphanet:158772	Nodular urticaria pigmentosa
KIT	Orphanet:158775	Smoldering systemic mastocytosis
KIT	Orphanet:158778	Isolated bone marrow mastocytosis
KIT	Orphanet:280785	Bullous diffuse cutaneous mastocytosis
KIT	Orphanet:280794	Pseudoxanthomatous diffuse cutaneous mastocytosis
KIT	Orphanet:2884	Piebaldism
KIT	Orphanet:44890	Gastrointestinal stromal tumor
KIT	Orphanet:566393	Acute mast cell leukemia
KIT	Orphanet:566396	Chronic mast cell leukemia
KIT	Orphanet:79455	Cutaneous mastocytoma
KIT	Orphanet:842	Testicular seminomatous germ cell tumor
KIT	Orphanet:90389	Telangiectasia macularis eruptiva perstans
KIT	Orphanet:98829	Acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)
KIT	Orphanet:98834	Acute myeloblastic leukemia with maturation
KIT	Orphanet:98849	Systemic mastocytosis with associated hematologic neoplasm

Cohort genes → proteins

2 cohort genes, 2 distinct canonical proteins.

Evidence partition

Subset	Genes
civic_only	2

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
ALK	HGNC:427	ENSG00000171094	Q9UM73	ALK tyrosine kinase receptor	civic_evidence
KIT	HGNC:6342	ENSG00000157404	P10721	Mast/stem cell growth factor receptor Kit	civic_evidence

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
ALK	ALK tyrosine kinase receptor	Neuronal receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis and differentiation of the nervous system.
KIT	Mast/stem cell growth factor receptor Kit	Tyrosine-protein kinase that acts as a cell-surface receptor for the cytokine KITLG/SCF and plays an essential role in the regulation of cell survival and proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell develo…

Protein-family classification

Druggable: 2 · Difficult: 0 · Unknown: 0 · Druggable fraction: 1.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Kinase	2	27.7×	0.001

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
ALK	Kinase	yes	2.7.10.1	Prot_kinase_dom, MAM_dom, Ser-Thr/Tyr_kinase_cat_dom
KIT	Kinase	yes	2.7.10.1	Prot_kinase_dom, Ser-Thr/Tyr_kinase_cat_dom, Tyr_kinase_rcpt_3_CS

Expression context

Cohort genes with no expression data: 0.

2 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	2
unknown	0

Top tissues across cohort

Tissue	Cohort genes
male germ cell	1
male germ line stem cell (sensu Vertebrata) in testis	1
sperm	1
lateral nuclear group of thalamus	1
oocyte	1
secondary oocyte	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
ALK	181	broad	marker	sperm, male germ cell, male germ line stem cell (sensu Vertebrata) in testis
KIT	263	broad	marker	lateral nuclear group of thalamus, secondary oocyte, oocyte

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
KIT	6,087
ALK	4,792

Structural data

PDB: 2 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
ALK	Q9UM73	79
KIT	P10721	52

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 52. Enrichment computed across 2 evidence-associated genes (2 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Dasatinib-resistant KIT mutants	1	5710.0×	5e-04	KIT
Imatinib-resistant KIT mutants	1	5710.0×	5e-04	KIT
KIT mutants bind TKIs	1	5710.0×	5e-04	KIT
Masitinib-resistant KIT mutants	1	5710.0×	5e-04	KIT
Nilotinib-resistant KIT mutants	1	5710.0×	5e-04	KIT
Regorafenib-resistant KIT mutants	1	5710.0×	5e-04	KIT
Signaling by kinase domain mutants of KIT	1	5710.0×	5e-04	KIT
Sunitinib-resistant KIT mutants	1	5710.0×	5e-04	KIT
Signaling by juxtamembrane domain KIT mutants	1	5710.0×	5e-04	KIT
Sorafenib-resistant KIT mutants	1	5710.0×	5e-04	KIT
Drug resistance of KIT mutants	1	5710.0×	5e-04	KIT
Signaling by extracellular domain mutants of KIT	1	5710.0×	5e-04	KIT
Drug resistance of ALK mutants	1	5710.0×	5e-04	ALK
ASP-3026-resistant ALK mutants	1	5710.0×	5e-04	ALK
NVP-TAE684-resistant ALK mutants	1	5710.0×	5e-04	ALK
alectinib-resistant ALK mutants	1	5710.0×	5e-04	ALK
brigatinib-resistant ALK mutants	1	5710.0×	5e-04	ALK
ceritinib-resistant ALK mutants	1	5710.0×	5e-04	ALK
crizotinib-resistant ALK mutants	1	5710.0×	5e-04	ALK
lorlatinib-resistant ALK mutants	1	5710.0×	5e-04	ALK
Diseases of signal transduction by growth factor receptors and second messengers	2	56.8×	8e-04	ALK, KIT
Signaling by Receptor Tyrosine Kinases	2	51.7×	9e-04	ALK, KIT
MDK and PTN in ALK signaling	1	1427.5×	0.002	ALK
Signaling by KIT in disease	1	571.0×	0.004	KIT
ALK mutants bind TKIs	1	475.8×	0.004	ALK
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors	1	380.7×	0.005	KIT
Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors	1	317.2×	0.006	KIT
Developmental Lineage of Mammary Gland Alveolar Cells	1	317.2×	0.006	KIT
Regulation of KIT signaling	1	300.5×	0.006	KIT
Signaling by ALK	1	285.5×	0.006	ALK

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
melanocyte adhesion	1	8426.0×	0.002	KIT
positive regulation of pyloric antrum smooth muscle contraction	1	8426.0×	0.002	KIT
positive regulation of colon smooth muscle contraction	1	8426.0×	0.002	KIT
protein autophosphorylation	2	145.3×	0.002	ALK, KIT
regulation of cell population proliferation	2	115.4×	0.002	ALK, KIT
response to environmental enrichment	1	4213.0×	0.002	ALK
positive regulation of vascular associated smooth muscle cell differentiation	1	4213.0×	0.002	KIT
Fc receptor signaling pathway	1	2808.7×	0.002	KIT
Kit signaling pathway	1	2808.7×	0.002	KIT
melanocyte migration	1	2808.7×	0.002	KIT
obsolete regulation of bile acid metabolic process	1	2808.7×	0.002	KIT
positive regulation of small intestine smooth muscle contraction	1	2808.7×	0.002	KIT
mast cell chemotaxis	1	2106.5×	0.002	KIT
hematopoietic stem cell migration	1	2106.5×	0.002	KIT
regulation of dopamine receptor signaling pathway	1	2106.5×	0.002	ALK
mast cell differentiation	1	2106.5×	0.002	KIT
positive regulation of dendritic cell cytokine production	1	1685.2×	0.002	KIT
positive regulation of mast cell cytokine production	1	1685.2×	0.002	KIT
swimming behavior	1	1685.2×	0.002	ALK
mast cell proliferation	1	1685.2×	0.002	KIT
positive regulation of mast cell proliferation	1	1685.2×	0.002	KIT
lymphoid progenitor cell differentiation	1	1404.3×	0.003	KIT
erythropoietin-mediated signaling pathway	1	1404.3×	0.003	KIT
myeloid progenitor cell differentiation	1	1203.7×	0.003	KIT
immature B cell differentiation	1	1203.7×	0.003	KIT
glycosphingolipid metabolic process	1	1203.7×	0.003	KIT
response to stress	1	1203.7×	0.003	ALK
tongue development	1	1053.2×	0.003	KIT
primordial germ cell migration	1	936.2×	0.003	KIT
peptidyl-tyrosine autophosphorylation	1	936.2×	0.003	ALK

Therapeutics

Drug target analysis

Approved (phase 4): 2 · Phase ≥3: 2 · Phased (≥1): 2 · Undrugged: 0

Druggability breadth: 2 of 2 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
ALK	CERITINIB
KIT	PONATINIB

Top cohort targets by molecule count

Symbol	Molecules	Max phase
KIT	99	4
ALK	61	4

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
CERITINIB	4	ALK, KIT
BOSUTINIB	4	ALK, KIT
CRIZOTINIB	4	ALK, KIT
ALECTINIB	4	ALK
ENTRECTINIB	4	ALK, KIT
LORLATINIB	4	ALK
GILTERITINIB	4	ALK
OSIMERTINIB	4	ALK
BRIGATINIB	4	ALK, KIT
REPOTRECTINIB	4	ALK
FEDRATINIB	4	ALK, KIT
RUXOLITINIB	4	ALK, KIT
INFIGRATINIB PHOSPHATE	4	ALK, KIT
INFIGRATINIB	4	ALK, KIT
PALBOCICLIB	4	ALK
VANDETANIB	4	ALK, KIT
UPADACITINIB	4	ALK
PAZOPANIB	4	ALK, KIT
NINTEDANIB	4	ALK, KIT
SUNITINIB	4	ALK, KIT
ERLOTINIB	4	ALK, KIT
MIDOSTAURIN	4	ALK, KIT
PONATINIB	4	KIT
TIVOZANIB	4	KIT
LENVATINIB	4	KIT
AXITINIB	4	KIT
SORAFENIB	4	KIT
DASATINIB ANHYDROUS	4	KIT
NICLOSAMIDE	4	KIT
IMATINIB MESYLATE	4	KIT

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 2.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
KIT	2,305	Binding:2242, ADMET:32, Functional:22, Toxicity:9
ALK	1,815	Binding:1801, Functional:13, ADMET:1

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
ALK	2.7.10.1	receptor protein-tyrosine kinase
KIT	2.7.10.1	receptor protein-tyrosine kinase

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
ALK	1,815
KIT	2,305

Pharmacogenomics

Cohort genes with a PharmGKB record: 2; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Drug repurposing candidates

28 approved/phased drugs hit cohort targets but don’t yet appear in disease-level clinical trials. Target-inhibition rationale is strongest for cancer driver genes; a bioactivity hit is a screening signal, not a treatment claim.

Compound	Max phase	Cohort target (bioactivity)
CERITINIB	4	ALK, KIT
BOSUTINIB	4	ALK, KIT
CRIZOTINIB	4	ALK, KIT
ALECTINIB	4	ALK
ENTRECTINIB	4	ALK, KIT
LORLATINIB	4	ALK
GILTERITINIB	4	ALK
OSIMERTINIB	4	ALK
BRIGATINIB	4	ALK, KIT
REPOTRECTINIB	4	ALK
FEDRATINIB	4	ALK, KIT
RUXOLITINIB	4	ALK, KIT
INFIGRATINIB PHOSPHATE	4	ALK, KIT
INFIGRATINIB	4	ALK, KIT
PALBOCICLIB	4	ALK
VANDETANIB	4	ALK, KIT
UPADACITINIB	4	ALK
PAZOPANIB	4	ALK, KIT
NINTEDANIB	4	ALK, KIT
SUNITINIB	4	ALK, KIT
ERLOTINIB	4	ALK, KIT
MIDOSTAURIN	4	ALK, KIT
PONATINIB	4	KIT
TIVOZANIB	4	KIT
LENVATINIB	4	KIT
DASATINIB ANHYDROUS	4	KIT
NICLOSAMIDE	4	KIT
IMATINIB MESYLATE	4	KIT

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	2	ALK, KIT
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	0

Undrugged target profiles

0 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Clinical trials & evidence

Clinical trials

Clinical trials: 61.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	40
PHASE1	10
Not specified	4
PHASE3	3
PHASE1/PHASE2	3
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02506153	PHASE3	ACTIVE_NOT_RECRUITING	Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
NCT00110019	PHASE3	COMPLETED	Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
NCT01989572	PHASE3	COMPLETED	Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery
NCT00937937	PHASE2	ACTIVE_NOT_RECRUITING	Dinaciclib in Treating Patients With Stage IV Melanoma
NCT03241186	PHASE2	ACTIVE_NOT_RECRUITING	Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma
NCT03611868	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors
NCT03698019	PHASE2	ACTIVE_NOT_RECRUITING	A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma
NCT04511013	PHASE2	RECRUITING	A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
NCT04645680	PHASE2	ACTIVE_NOT_RECRUITING	Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving Immunotherapy
NCT05086692	PHASE1/PHASE2	RECRUITING	A Beta-only IL-2 ImmunoTherapY Study
NCT05111574	PHASE2	RECRUITING	Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
NCT05384496	PHASE2	RECRUITING	Axitinib and Nivolumab for the Treatment of Mucosal Melanoma
NCT06319196	PHASE2	RECRUITING	Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma
NCT06999980	PHASE2	RECRUITING	Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)
NCT07155317	PHASE2	RECRUITING	Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial
NCT07230613	PHASE2	RECRUITING	Neo-adjuvant Immunotherapy in Patients With Localized Melanoma
NCT07236528	PHASE2	NOT_YET_RECRUITING	Combination of Carilizumab, Apatinib, and Radiotherapy for Advanced Mucosal Melanoma
NCT07347444	PHASE2	NOT_YET_RECRUITING	Iparomlimab and Tuvoraleimab Injection in Combination With Bevacizumab, Albumin-bound Paclitaxel, and Carboplatin as First- or Second-line Treatment for Patients With Advanced Acral and Mucosal Melanoma
NCT07400302	PHASE2	RECRUITING	Sintilimab Combined With Chemotherapy for Adjuvant Treatment of Mucosal Melanoma After Surgery
NCT07576725	PHASE2	NOT_YET_RECRUITING	Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
NCT00085189	PHASE2	COMPLETED	Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma
NCT00424515	PHASE2	COMPLETED	Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma
NCT01166126	PHASE2	TERMINATED	Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV
NCT01961115	PHASE2	COMPLETED	Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma
NCT02126579	PHASE1/PHASE2	COMPLETED	Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists
NCT02129075	PHASE2	COMPLETED	A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma
NCT02158520	PHASE2	COMPLETED	Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery
NCT02519322	PHASE2	COMPLETED	Neoadjuvant and Adjuvant Checkpoint Blockade
NCT02978443	PHASE2	TERMINATED	A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab
NCT03033576	PHASE2	COMPLETED	Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma
NCT03138642	PHASE2	UNKNOWN	Mucosal Melanoma of Head and Neck in Intensity-modulated Radiotherapy Era
NCT03178123	PHASE2	UNKNOWN	The Study of JS001 Compared to High-Dose Interferon In Patients With Mucosal Melanoma That Has Been Removed by Surgery
NCT03220009	PHASE2	WITHDRAWN	Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma
NCT03602547	PHASE2	UNKNOWN	Study of the Combination of CM082 With JS001 in Patients With Advanced Mucosal Melanoma.
NCT03941795	PHASE2	UNKNOWN	Phase II Study in the Treatment of Patients With Advanced Mucinous Melanoma
NCT03986515	PHASE2	UNKNOWN	Apatinib Plus SHR1210 in Advanced Mucosal Melanoma
NCT04180995	PHASE2	UNKNOWN	Toripalimab in Combination With Axitinib in Patients With Localized Mucosal Melanoma
NCT04462965	PHASE2	UNKNOWN	Postoperative Adjuvant Treatment of Completely Resected Mucosal Melanoma Phase II Study
NCT04472806	PHASE2	UNKNOWN	Maintenance Treatment of Toripalimab(JS001) in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma
NCT04622566	PHASE2	UNKNOWN	Lenvatinib and Pembrolizumab in Resectable Mucosal Melanoma

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
TORIPALIMAB	4	4
SORAFENIB	4	3
AXITINIB	4	1
BINIMETINIB	4	1
CABOZANTINIB	4	1
CISPLATIN	4	1
ENCORAFENIB	4	1
IPILIMUMAB	4	1
PEMBROLIZUMAB	4	1
RELATLIMAB	4	1
SARGRAMOSTIM	4	1
SELUMETINIB	4	1
TEMSIROLIMUS	4	1
TYROSINASE	3	2
AGATOLIMOD SODIUM	3	1
DINACICLIB	3	1
EPACADOSTAT	3	1
GP-100 ANTIGEN	3	1
INCOMPLETE FREUND’S ADJUVANT	3	1
HILTONOL	2	2
NEMVALEUKIN ALFA	2	1
RESIQUIMOD	2	1
VACTOSERTIB	2	1
YH-003	2	1
CHEMBL2369717	0	2
CHEMBL3939307	0	2
CHEMBL2006674	0	1
CHEMBL5171657	0	1
CHEMBL5408374	0	1
CHEMBL4463209	0	1

Precision-medicine subtype map (CIViC)

Drug × molecular subtype: 3 predictive associations from 3 curated evidence items.

Molecular subtype	Therapy	Effect	Level	CIViC
KIT Amplification	Imatinib	Resistance	CIViC B	EID1466
ALK Alternative Transcript (ATI)	Entrectinib	Sensitivity/Response	CIViC C	EID7421
KIT K642E	Imatinib	Sensitivity/Response	CIViC C	EID2889